ReviewMaterials today. Bio2024
Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study.
Review in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Organoid Models to Study Human Infectious Diseases.Cell proliferation · 2025Review
- Review
- Biological Barrier Models-on-Chips: A Novel Tool for Disease Research and Drug Discovery.Biosensors · 2025Review
- Novel Approach Methodologies in Modeling Complex Bioaerosol Exposure in Asthma and Allergic Rhinitis Under Climate Change.Expert reviews in molecular medicine · 2025Review
- Establishment of a 3D-Printed Tissue-on-a-Chip Model for Live Imaging of Bacterial Infections.Advances in experimental medicine and biology · 2025Article
- Immune organoids: emerging platforms for modeling and analyzing human adaptive immunity.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), characterized by its high fatality rate and contagious nature, has led to significant morbidity and mortality worldwide, significantly impacting both our daily lives and public health. The respiratory pathway serves as the primary route for SARS-CoV2 propagation within the human body, with the lung acting as the initial target organ. Simultaneously, the lung functions as a protective barrier, preventing the entry of viruses into the bloodstream through the alveolar-capillary barrier. Bioengineered microfluidic lung chips, utilizing advanced near-to-native technologies, offer a novel perspective for comprehending the intricate workings of human lungs and facilitating the discovery of anti-coronavirus drugs to combat the challenges posed by coronavirus disease 2019 (COVID-19). This review aims to introduce the key elements and design types of artificial lung chips that closely resemble
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.